非小细胞肺癌前瞻性评分肺毒性:随机II期剂量递增试验结果
该研究基于丹麦五中心2009-2013年随机II期剂量递增试验,纳入IIB-IIIB期NSCLC患者,比较60 Gy/30fx(A组59例)与66 Gy/33fx(B组58例)同步放化疗后≥2级放射性肺炎(RP)发生率。结果显示两组RP≥G2无显著差异(41%对52%,p=0.231),单因素分析发现GTV大小、感染、基线呼吸困难及放疗中咳嗽加重为RP风险因素。
要点
- 高剂量组与低剂量组≥2级RP发生率无统计学差异(41%对52%,p=0.231)。
- GTV大小、基线或放疗中感染、基线呼吸困难、放疗中咳嗽加重与RP≥G2相关。
- 多变量模型预测效能有限,样本量不足以建立稳健多变量模型。
核心结论
- 高剂量组(66 Gy/33fx)与低剂量组(60 Gy/30fx)在≥2级放射性肺炎风险上无统计学差异。
- 单因素分析识别出GTV大小、感染、基线呼吸困难及放疗中咳嗽加重为RP≥G2的风险因素。
研究设计与样本
- 国家性随机II期剂量递增试验,2009至2013年丹麦五个放疗中心开展。
- 纳入组织学证实的IIB-IIIB期NSCLC患者,接受同步放化疗(口服长春瑞滨每周3次)。
- A组60 Gy/30fx共59例,B组66 Gy/33fx共58例。
- 采用CTCAEv3.0前瞻性评分≥2级放射性肺炎,进行单因素分析、多变量逻辑回归及Cox回归。
主要发现
- 高剂量组平均肺剂量中位数14.9 Gy(范围5.8-23.1),低剂量组17.5 Gy(范围8.6-24.8),p=0.075。
- ≥2级RP发生率A组41%、B组52%,p=0.231。
- 至≥2级RP时间的Kaplan-Meier分析两组比较p=0.180。
- 单因素分析中GTV大小OR=2.091/100 cm3(p=0.002),感染OR=8.087(p=0.026),基线呼吸困难OR=2.184(p=0.044),放疗中咳嗽加重OR=2.787(p=0.008)。
- 多变量逻辑回归和Cox回归中最优预测模型的偏差在零模型一个标准差以内。
关键数值与推荐
- 放射性肺炎分级采用CTCAEv3.0标准,研究终点为≥2级RP。
- 单因素分析显示GTV大小每增加100 cm3,RP≥G2风险OR=2.091(p=0.002)。
- 基线或放疗中感染与RP≥G2风险OR=8.087(p=0.026)。
- 基线呼吸困难与RP≥G2风险OR=2.184(p=0.044)。
- 放疗中咳嗽加重与RP≥G2风险OR=2.787(p=0.008)。
临床怎么用
- 对于局部晚期NSCLC同步放化疗患者,应关注GTV大小、基线呼吸困难、感染及放疗中咳嗽变化以评估RP风险。
- 高剂量至66 Gy/33fx未显著增加≥2级RP风险,但需结合其他因素个体化评估。
局限性
- 患者数量太少,无法建立统计上稳健的多变量模型。
- 多变量模型预测效能有限,最优模型偏差在零模型一个标准差以内。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prospectively scored radiation pneumonitis (RP) observed in a national, randomized phase II dose-escalation trial for patients with locally advanced non-small cell lung cancer (NSCLC) was investigated. METHODS: Patients with stage IIB-IIIB histologically proven NSCLC were treated with concomitant chemo-radiotherapy (oral Vinorelbine 3times/week) at 60 Gy/30fx (A-59pts) and 66 Gy/33fx (B-58pts) from 2009 to 2013 at five Danish RT centers. Grade 2 RP (CTCAEv3.0) was investigated with univariate analysis for association with clinical and dosimetric parameters, including dyspnea and cough at baseline and during RT. Multivariable logistic regression and Cox regression with regularization were used to find a multivariable model for RP ≥ G2. RESULTS: Despite a tendency of higher mean lung dose in the high-dose arm (median[range] A = 14.9 Gy[5.8,23.1], B = 17.5 Gy[8.6,24.8], p = 0.075), pulmonary toxicities were not significantly different (RP ≥ G2 41%(A) and 52%(B), p = 0.231). A Kaplan Meier analysis of the time to RP ≥ G2 between the two arms did not reach statistical significance (p = 0.180). Statistically significant risk factors for RP ≥ G2 were GTV size (OR = 2.091/100 cm3, p = 0.002), infection at baseline or during RT (OR = 8.087, p = 0.026), dyspnea at baseline (OR = 2.184, p = 0.044) and increase of cough during RT (OR = 2.787, p = 0.008). In the multivariable logistic regression and the Cox regression analysis, the deviances of the most predictive models were within one standard deviation of the null model. CONCLUSION: No statistical difference between the high- and low dose arm was found in the risk of developing RP. The univariate analysis identified target volume, infection, dyspnea at baseline, and increase of cough during RT as risk factors for RP. The number of patients was too small to establish a statistically sound multivariable model.
引用
- Lutz CM, Knap MM, Hoffmann L, et al. Prospectively scored pulmonary toxicities in non-small cell lung cancer: Results from a randomized phase II dose escalation trial. Clin Transl Radiat Oncol. 2020. PMID: 33385069. doi:10.1016/j.ctro.2020.11.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。